Search results for "Bromide"
showing 10 items of 591 documents
CCDC 1833436: Experimental Crystal Structure Determination
2019
Related Article: Antti Tiihonen, Manu Lahtinen|2019|CrystEngComm|21|2286|doi:10.1039/C8CE01015C
CCDC 1434341: Experimental Crystal Structure Determination
2016
Related Article: Shobhraj Haldar, Gonela Vijaykumar, Aloke Kumar Ghosh, Luca Carrella, Manindranath Bera|2017|Polyhedron|121|130|doi:10.1016/j.poly.2016.09.064
CCDC 1529942: Experimental Crystal Structure Determination
2017
Related Article: Hervé Feuchter, Guillaume Ortiz, Yoann Rousselin, Alla Bessmertnykh-Lemeune, and Stéphane Brandès|2017|Cryst.Growth Des.|17|3665|doi:10.1021/acs.cgd.7b00217
CCDC 1040203: Experimental Crystal Structure Determination
2016
Related Article: Markus Albrecht, Yi Hai, Okan Köksal, Gerhard Raabe, Fangfang Pan, Arto Valkonen and Kari Rissanen|2016|Chem.-Eur.J.|22|6596|doi:10.1002/chem.201600249
CCDC 831306: Experimental Crystal Structure Determination
2012
Related Article: M.Giese, M.Albrecht, G.Ivanova, A.Valkonen, K.Rissanen|2012|Supramol.Chem.|24|48|doi:10.1080/10610278.2011.622384
CCDC 282424: Experimental Crystal Structure Determination
2006
Related Article: H.Mansikkamaki, S.Busi, M.Nissinen, A.Ahman, K.Rissanen|2006|Chem.-Eur.J.|12|4289|doi:10.1002/chem.200501201
Detection and localisation of disulphide bonds in a synthetic peptide reproducing the sequence 1-30 of Par j 1.0101 by electrospray ionisation mass s…
2001
The structural characterisation of a synthetic peptide reproducing the sequence 1–30 of Par j 1.0101, a major allergenic protein present in the pollen of Parietaria judaica, by combined use of chemical and enzymatic cleavage, reversed-phase high-performance liquid chromatography (RP-HPLC) and electrospray ionisation mass spectrometry (ESI-MS), is described. Direct ESI-MS of the synthetic peptide after reaction with methyl iodide showed that the product is a mixture of two peptides: one form in which two out of the four cysteine residues present in the sequence are oxidised and a minor amount of another form in which all the cysteines are fully reduced. It was ascertained, using the combined…
Entrapment of amino acids in gas phase surfactant assemblies: The case of tryptophan confined in positively charged (1R,2S)-dodecyl (2-hydroxy-1-meth…
2017
The ability of positively charged aggregates of the surfactant (1R,2S)‐dodecyl (2‐hydroxy‐1‐methyl‐2‐phenylethyl))dimethylammonium bromide (DMEB) to incorporate D-tryptophan or L-tryptophan in the gas phase has been investigated by electrospray ion mobility mass spectrometry (ESIâIMâMS). Strongly impacted by the pH of the electrosprayed solutions, both protonated (T+) and deprotonated (T-) tryptophan are effectively included into the aggregates, whereas, tryptophan in zwitterionic (T0) form is practically absent in singly charged DMEB aggregates but can be found in multiply charged ones. The ability to incorporate tryptophan increases with the aggregation number and charge state of aggr…
Synthesis of platinum complexes with 2-(5-perfluoroalkyl-1,2,4-oxadiazol-3yl)-pyridine and 2-(3-perfluoroalkyl-1-methyl-1,2,4-triazole-5yl)-pyridine …
2016
Five new mononuclear Pt(II) complexes with 5-perfluoroalkyl-1,2,4-oxadiazolyl-pyridine and 3-perfluoroalkyl-1,2,4-triazolyl-pyridine ligands are reported. The ligands 2-(5-perfluoroheptyl-1,2,4-oxadiazole-3yl)-pyridine (pfhop), 2-(5-perfluoropropyl)-1,2,4-oxadiazole-3yl)-pyridine (pfpop), 2-(3-perfluoroheptyl-1-methyl-1,2,4-triazole-5yl)-pyridine (pfhtp), 2-(3-perfluoropropyl-1-methyl-1,2,4-triazole-5yl)-pyridine (pfptp) and their complexes [PtCl2(pfhop)(2)]center dot 1.5 DMSO (2a), [PtCl2(pfpop)(2)]center dot 1.5 DMSO (3a), [PtCl2(pfhtp)(2)]center dot 1.5 DMSO (4a), PtCl2(pfhtp) (4b), [PtCl2(PfPtP)(2)]center dot 1.5 DMSO (5a) have been synthesized and structurally characterized. The comple…
The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.
2014
BackgroundTiotropium, a once-daily long-acting anticholinergic bronchodilator, has demonstrated efficacy in patients with asthma who were symptomatic despite treatment with medium- to high-dose inhaled corticosteroids (ICS).ObjectiveThe objective of this study was to evaluate the efficacy and safety of once-daily tiotropium Respimat (5 μg or 2.5 μg), compared with placebo Respimat, as add-on therapy to low- to medium-dose ICS for adults with symptomatic asthma.MethodsA phase III, double-blind, placebo-controlled trial was conducted (NCT01316380). Adults with symptomatic asthma receiving low- to medium-dose ICS (200-400 μg budesonide or equivalent dose) and a pre-bronchodilator forced expira…